NCT00264108 2014-05-07
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
Janssen-Cilag B.V.
Completed
Clinical Trials
13 trialsNCT00401544 2014-01-29
Darbepoetin Alfa With or Without Intravenous (IV) Iron
Amgen
Phase 2 Completed
NCT00989092 2014-01-29
Darbepoetin Alfa and Anemia of Cancer
Amgen
Phase 2 Terminated
NCT00386152 2013-07-19
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00144131 2013-05-24
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
Amgen
Phase 2 Completed
NCT00135317 2013-05-23
AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
Amgen
Phase 3 Completed
NCT00091858 2013-05-08
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Amgen
Phase 3 Completed
NCT00111462 2013-05-08
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
Amgen
Phase 2 Completed
NCT00239239 2010-03-05
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
Amgen
Phase 2 Completed
NCT00115167 2009-05-11
A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study
Amgen
Phase 3 Completed
NCT00120705 2009-03-25
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
Amgen
Phase 2 Completed
NCT00119613 2008-08-08
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
Amgen
Phase 3 Completed
NCT00111137 2008-02-28
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
Amgen
Phase 3 Completed